← Leaderboards
Thomas J Gardner
Sloan-Kettering Inst Can Research
$162,155
Attributed
$162,155
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $61.6K · FY2018–20$100K$75K$50K$25K$0
'18
'19
'20
Funding mix
By agency
NIH$162,155 · 1
By mechanism
F32$162,155 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Katharine C Hsu$29,362,365
- Joseph Chai-Yuen Sun$17,368,196
- Taha Merghoub$4,342,237
- Craig B Thompson$56,520,903
- Shakeel Modak$2,048,034
Others in their field
Other Emerging Leaders on “Adoptive Transfer”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Bronwen Shaw · Medical College Of Wisconsin$10,707,191
- Colin Masters · University Of Melbourne$10,651,748
- Akila Subramaniam · University Of Alabama At Birmingham$6,547,544
- Sarah Emily Snider · Beam Diagnostics, Inc.$5,670,978
- Pradeep Natarajan · Massachusetts General Hospital$4,959,712
Research focus
Adoptive TransferAffectAnimal ModelAnimalsAntigensAntigen-Specific T CellsAntineoplastic AgentsBaseCancer CellCancerousCancer TherapyCancer TypeCarboxypeptidaseCar T Cell TherapyCd19 GeneCellsCell SurfaceCell TherapyCessation Of LifeChemotherapyChimeric Antigen ReceptorChimeric Antigen Receptor T CellsCleaved CellAdoptive Cell Transfers
Grant awards (3)
Creating a targeted micropharmacy for improved cellular cancer therapies$41,891
F32 · FY2020 · CA · contact PI
Creating a targeted micropharmacy for improved cellular cancer therapies$61,610
F32 · FY2019 · CA · contact PI
Creating a targeted micropharmacy for improved cellular cancer therapies$58,654
F32 · FY2018 · CA · contact PI